İzole idiopatik büyüme hormonu eksikliği (İİBHE) tanı kriterleri ve bunun idiopatik kısa boy (İKB) ile Konstutisyonel Büyüme Geriliği ve Puberte gecikmesinden (KBGPG) ayrımı konusunda tartışmalar sürmektedir. Biz de İİBHE tanısı alan bir grup hastada tedavi sırasında büyüme hormonu (BH) sekresyonunu ve retest sırasında normalleşme gösterenlerde büyüme hızını yeniden değerlendirdik. İİBHE olan 17 hastada rekombinant insan büyüme Hormonu (riBH) ile tedaviye başlandıktan 2.76±1.78 yıl sonra BH uyarı testleri tekrarlandı ve testlerde normalleşme gösteren olguların tedavisi kesilerek 6-12 ay süreyle izlendi. Retest sırasında 11 olgu (%64.6) normal BH sekresyonu (BH piki>15 mlU/L) ve 6 olgu (%35.4) yetersiz sekresyon gösterdi (BH piki

There has been a continuing discussion about criteria of diagnosing isolated idiopathic growth hormone deficiency (IIGHD) and differentiating this entity from idiopathic short stature (ISS) and constitutional delay of growth and puberty (CDGP). For further confirmation, we reevaluated GH secretion during replacement therapy on a group of patients with IIGHD and followed height velocity in a smaller group showing normalization at retesting. Seventeen children (five girls and twelve boys) having IIGHD underwent G H stimulation test 2.76±1.78 years after recombinant human growth hormone (rhGH) therapy and those showed normalization were followed for further 6-12 months after cessation of rhGH therapy. During retesting, eleven (%64.6) presented normal secretion (GH peak >15mIU/L) and six (%35.4) insufficient secretion of G H (G H peak <15mIU/L). Six patients entered puberty during retesting, only one showing insufficient secretion while others presented normalization. Pretreatment auxologic characteristics and response to rhGH therapy were similar in both of the groups which showed normal and insufficient secretion. Of the eleven subjects presented normal secretion at retesting, nine showed poor growth and decreased height SDS at the end of the following period after cessation of treatment. This study has indicated that GH secretion normalization at retesting may not necessarily represent the end of a transient secretory defect. Majority of the patients that revealed normalization at retesting, showed poor growth later in default of rhGH therapy.